Drug Makers, Pharma ETFs Face a Tough Earnings Season

The healthcare sector has been lackluster this earnings season, and without supporting factors such as price increases or increased mergers and acquisitions to bolster the segment, pharmaceutical exchange traded funds could suffer through a weak start to the second quarter. Year-to-date, the...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.